Updated as of May 31, 2019
1. Jakafi marketed by Incyte in the US; ruxolitinib licensed to Novartis ex-US 2. Adults with intermediate or high-risk myelofibrosis 3. Adults with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea 4. Adults and pediatric patients 12 years and older with steroid-refractory acute graft-versus-host disease 5. European rights to Iclusig licensed from ARIAD 6. In collaboration with AstraZeneca 7. In collaboration with MacroGenics 8. In collaboration with Merck 9. Co-development with Calithera 10. Discovery collaboration with Agenus 11. In collaboration with Merus 12. Worldwide rights to baricitinib licensed to Lilly: approved as Olumiant in multiple territories globally for certain patients with moderate to severe rheumatoid arthritis 13. Worldwide rights to capmatinib licensed to Novartis
The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.
We currently have a number of clinical trials underway in oncology and other areas of research interest. Incyte-sponsored studies can be found at www.IncyteClinicalTrials.com.
Incyte also supports significant independent research aimed at advancing the study of our products. A team of professionals scrutinizes all proposals submitted to Incyte for scientific merit and alignment with Incyte’s research goals. If you are interested in submitting a research proposal, please visit our online portal at iir.incyte.com.
Learn more about our target molecules currently in clinical development>
For questions concerning Investigator Initiated Research conducted outside of the US, please contact Incyte at Global_IIR@incyte.com.
For questions concerning Investigator Initiated Research conducted in the US, please contact Incyte at US_IIR@incyte.com.